Bahnhofstrasse 7
Zug 6300
Switzerland
41 41 711 9325
https://oculis.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 36
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Riad Sherif M.B.A., M.D. | CEO & Director | S.O. | S.O. | 1968 |
Ms. Sylvia Cheung | Chief Financial Officer | S.O. | S.O. | 1975 |
Dr. Ramin Tadayoni M.D., Ph.D. | Chief Scientific Officer | S.O. | S.O. | S.O. |
Ms. Virginia R. Dean | Chief Human Resources Officer | S.O. | S.O. | 1967 |
Dr. Bastian Dehmel M.D. | Chief Development Officer | S.O. | S.O. | 1971 |
Mr. Páll Ragnar Jóhannesson | Chief Business Officer | S.O. | S.O. | 1982 |
Ms. Rebecca Weil | Chief Commercial Officer | S.O. | S.O. | S.O. |
Dr. Snehal Shah Pharm.D. | President of Research & Development | S.O. | S.O. | S.O. |
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
L’ISS Governance QualityScore de Oculis Holding AG en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..